The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.

Cancer Res Commun · 2025 · PMC11729160 · PMID 39679910

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, CD8 + , CD4 + , and CD163 + cell densities showed a trend of higher levels during T-DXd treatment ( Fig. 4A ; Supplementary Fig.

also in 53,322 other papers

a nonsignificant trendno p-value reported

In this study, we found a nonsignificant trend between various baseline immune cell densities and T-DXd efficacy and detected a significant difference between baseline CD20 + cell densities in responders and nonresponders.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.